Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Better Together: BioCryst, Idera Merge To Improve Rare Disease Position

Executive Summary

New company will have pair of Phase III candidates, an immuno-oncology licensing opportunity, strong experience in hereditary angioedema and roughly $243m in cash to position itself as a rare disease stronghold.

You may also be interested in...

BioCryst’s Oral Therapy For HAE Attacks On Track With Exploratory Phase II Success

Biocryst’s oral kallikrein inhibitor BCX7353 – already in Phase III for prophylaxis of hereditary angioedema – shows efficacy in a range of endpoints in a Phase II exploratory trial.

Deal Watch: BioCryst Shareholder Dissent Scuttles Planned Merger With Idera

AZ’s MedImmune to use 4D’s AAV vector technology to deliver therapies for chronic lung disease, while Roivant spinout Dermavant licenses Phase III-ready autoimmune candidate tapinarof from GSK.

Pharma Q4 Results Preview: Shire, Bayer, Merck KGaA

Potential upheavals in the hemophilia market bring uncertainty for Shire and Bayer, with executives likely to be quizzed on how they can retain market share during upcoming Q4 results calls. Scrip’s final earnings preview highlights the key challenges for large companies reporting at the tail-end of the earnings season.

Related Content


Related Companies

Related Deals




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts